Effect of add-on pentoxifylline on proteinuria in membranous glomerulonephritis: A 6-month placebo-controlled trial

Clinical Drug Investigation

Volumn 33, Issue 3, 2013, Pages 215-222

  Badri, Shirinsadat ^a   Dashti Khavidaki, Simin ^a   Ahmadi, Farrokhlegha ^a   Mahdavi Mazdeh, Mitra ^a   Abbasi, Mohammad Reza ^a   Khalili, Hossein ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; PROTEIN;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PRIVATE HOSPITAL; PROTEIN URINE LEVEL; PROTEINURIA; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; URINALYSIS; URINARY EXCRETION;

ADULT; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; MALE; MIDDLE AGED; PENTOXIFYLLINE; PLACEBOS; PROSPECTIVE STUDIES; PROTEINURIA; YOUNG ADULT;

EID: 84877042708     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0057-1     Document Type: Article

References (37)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-47.
2. van DijkPC, Jager KJ, de Charro F, et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant. 2001;16(6):1120-9.
3. Zandi-Nejad K, Eddy AA, Glassock RJ, et al. Why is proteinuria an ominous biomarker of progressive kidney disease? Kidney Int. 2004;Suppl(92):S76-89.
4. McCormick BB, Sydor A, Akbari A, et al. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis. 2008;52(3):454-63.
5. Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348(23):2285-93.
6. Hebert LA, Wilmer WA, Falkenhain ME, et al. Renoprotection: one or many therapies? Kidney Int. 2001;59(4):1211-26.
7. Mogensen CE, Neldam S, Tikkanen I, et al. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440-4.
8. Zoja C, Corna D, Camozzi D, et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol. 2002;13(12):2898-908.
9. Navarro JF, Mora C, Muros M, et al. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol. 2005;16(7):2119-26.
10. Ehrly AM. Improvement of the flow properties of blood: a new therapeutical approach in occlusive arterial disease. Angiology. 1976;27(3):188-96.
11. De Sanctis MT, Cesarone MR, Belcaro G, et al. Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial-walking distance and microcirculation. Angiology. 2002;53(Suppl 1):S7-12.
12. Gorson DM. Reduction of macroalbuminuria with pentoxifylline in diabetic nephropathy. Report of three cases. Diabetes Care. 1998;21(12):2190-1.
13. Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra JR, et al. Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol. 1995;43(2):116-21.
14. Navarro JF, Mora C. Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy. Diabetes Care. 1999;22(6):1006-8.
15. Wilmer WA, Rovin BH, Hebert CJ, et al. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol. 2003;14(12):3217-32.
16. Usta Y, Ismailoglu UB, Bakkaloglu A, et al. Effects of pentoxifylline in adriamycin-induced renal disease in rats. Pediatr Nephrol. 2004;19(8):840-3.
17. Chen YM, Chien CT, Hu-Tsai MI, et al. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int. 1999;56(3):932-43.
18. Han KH, Han SY, Kim HS, et al. Prolonged administration enhances the renoprotective effect of pentoxifylline via antiinflammatory activity in streptozotocin-induced diabetic nephropathy. Inflammation. 2010;33(3):137-43.
19. Lin SL, Chiang WC, Chen YM, et al. The renoprotective potential of pentoxifylline in chronic kidney disease. J Chin Med Assoc. 2005;68(3):99-105.
20. Lin SL, Chen YM, Chiang WC, et al. Pentoxifylline: a potential therapy for chronic kidney disease. Nephrology (Carlton). 2004;9(4):198-204.
21. Chen YM, Lin SL, Chiang WC, et al. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int. 2006;69(8):1410-5.
22. Khoshakhlagh P, Bahrololoumi-Shapourabadi M, Mohammadirad A, et al. Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress. Toxicol Mech Methods. 2007;17(5):281-8.
23. Galindo-Rodriguez G, Bustamante R, Esquivel-Nava G, et al. Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis. J Rheumatol. 2003;30(11):2382-4.
24. Renke M, Tylicki L, Rutkowski P, et al. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. Acta Biochim Pol. 2010;57(1):119-23.
25. Ducloux D, Bresson-Vautrin C, Chalopin J. Use of pentoxifylline in membranous nephropathy. Lancet. 2001;357(9269):1672-3.
26. Kshirsagar AV, Nachman PH, Falk RJ. Alternative therapies and future intervention for treatment of membranous nephropathy. Semin Nephrol 2003;23(4):362-72.
27. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-70.
28. Badri S, Dashti-Khavidaki S, Lessan-Pezeshki M, et al. A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. J Pharm Pharmaceut Sci. 2011;14(1):128-37.
29. Shan D, Wu HM, Yuan QY, et al. Pentoxifylline for diabetic kidney disease. Cochrane Database Syst Rev. 2012;2.
30. Rodriguez-Moran M, Guerrero-Romero F. Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes. Curr Diabetes Rev. 2008;4(1):55-62.
31. Solera MJ, Riera M, Gutierrezb A, et al. New options and perspectives for proteinuria management after kidney transplantation. Transplant Rev. 2012;26:44-52.
32. Turgut F, Bolton WK. Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis. 2010;55(5):928-40.
33. Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol. 2009;5(7):375-83.
34. Ravera M, Re M, Weiss U, et al. Emerging therapeutic strategies in diabetic nephropathy. J Nephrol 2007;20(Suppl 12):S23-32.
35. Kshirsagar AV, Nachman PH, Falk RJ. Alternative therapies and future intervention for treatment of membranous nephropathy. Semin Nephrol 2003;23(4):362-72.
36. Roozbeh J, Banihashemi MA, Ghezlou M, et al. Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy. Ren Fail. 2010;32(2):172-8.
37. Perkins RM, Aboudara MC, Uy AL, et al. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2009;53(4):606-16.